The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Research Report 2025
Synopsis
Duchenne muscular dystrophy, sometimes shortened to DMD or just Duchenne, is a rare genetic disease. It predominantly affects males, but, in rare cases, can also affect females. Duchenne causes the muscles in the body to become weak and damaged over time and is eventually fatal. The genetic change that causes Duchenne—a mutation in the DMD gene—happens before birth and can be inherited, or new mutations in the gene can occur spontaneously. Muscle weakness becomes increasingly noticeable between the ages of 3 and 5, and most patients use a wheelchair by the time they are 12. During adolescence, heart and breathing muscles weaken, leading to serious, life-threatening complications.
The global Duchenne Muscular Dystrophy (DMD) Therapeutics market was valued at US$ 1329.2 million in 2023 and is anticipated to reach US$ 15940 million by 2030, witnessing a CAGR of 42.1% during the forecast period 2024-2030.
By region, North America has the highest market share, reaching 70.66% in 2019.
Sarepta Therapeutics and PTC Therapeutics hold amlost the whole market.
This report aims to provide a comprehensive presentation of the global market for Duchenne Muscular Dystrophy (DMD) Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Duchenne Muscular Dystrophy (DMD) Therapeutics.
Report Scope
The Duchenne Muscular Dystrophy (DMD) Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Duchenne Muscular Dystrophy (DMD) Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Duchenne Muscular Dystrophy (DMD) Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Sarepta Therapeutics
PTC Therapeutics
Pfizer
Bristol-Myers Squibb
Italfarmaco
Santhera Pharmaceuticals
Segment by Type
Exondys
Emflaza
Translarna
Segment by Application
Hospitals
Clinics
Home Care
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Duchenne Muscular Dystrophy (DMD) Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Duchenne muscular dystrophy, sometimes shortened to DMD or just Duchenne, is a rare genetic disease. It predominantly affects males, but, in rare cases, can also affect females. Duchenne causes the muscles in the body to become weak and damaged over time and is eventually fatal. The genetic change that causes Duchenne—a mutation in the DMD gene—happens before birth and can be inherited, or new mutations in the gene can occur spontaneously. Muscle weakness becomes increasingly noticeable between the ages of 3 and 5, and most patients use a wheelchair by the time they are 12. During adolescence, heart and breathing muscles weaken, leading to serious, life-threatening complications.
The global Duchenne Muscular Dystrophy (DMD) Therapeutics market was valued at US$ 1329.2 million in 2023 and is anticipated to reach US$ 15940 million by 2030, witnessing a CAGR of 42.1% during the forecast period 2024-2030.
By region, North America has the highest market share, reaching 70.66% in 2019.
Sarepta Therapeutics and PTC Therapeutics hold amlost the whole market.
This report aims to provide a comprehensive presentation of the global market for Duchenne Muscular Dystrophy (DMD) Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Duchenne Muscular Dystrophy (DMD) Therapeutics.
Report Scope
The Duchenne Muscular Dystrophy (DMD) Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Duchenne Muscular Dystrophy (DMD) Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Duchenne Muscular Dystrophy (DMD) Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Sarepta Therapeutics
PTC Therapeutics
Pfizer
Bristol-Myers Squibb
Italfarmaco
Santhera Pharmaceuticals
Segment by Type
Exondys
Emflaza
Translarna
Segment by Application
Hospitals
Clinics
Home Care
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Duchenne Muscular Dystrophy (DMD) Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Exondys
1.2.3 Emflaza
1.2.4 Translarna
1.3 Market by Application
1.3.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Home Care
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Perspective (2019-2030)
2.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Growth Trends by Region
2.2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Dynamics
2.3.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Trends
2.3.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Drivers
2.3.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Challenges
2.3.4 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Duchenne Muscular Dystrophy (DMD) Therapeutics Players by Revenue
3.1.1 Global Top Duchenne Muscular Dystrophy (DMD) Therapeutics Players by Revenue (2019-2024)
3.1.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue
3.4 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Concentration Ratio
3.4.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue in 2023
3.5 Duchenne Muscular Dystrophy (DMD) Therapeutics Key Players Head office and Area Served
3.6 Key Players Duchenne Muscular Dystrophy (DMD) Therapeutics Product Solution and Service
3.7 Date of Enter into Duchenne Muscular Dystrophy (DMD) Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Duchenne Muscular Dystrophy (DMD) Therapeutics Breakdown Data by Type
4.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Type (2025-2030)
5 Duchenne Muscular Dystrophy (DMD) Therapeutics Breakdown Data by Application
5.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2019-2030)
6.2 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2019-2024)
6.4 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2019-2030)
7.2 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2019-2024)
7.4 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2019-2030)
8.2 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (2019-2024)
8.4 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2019-2030)
9.2 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2019-2024)
9.4 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2019-2030)
10.2 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2019-2024)
10.4 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Sarepta Therapeutics
11.1.1 Sarepta Therapeutics Company Detail
11.1.2 Sarepta Therapeutics Business Overview
11.1.3 Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction
11.1.4 Sarepta Therapeutics Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2019-2024)
11.1.5 Sarepta Therapeutics Recent Development
11.2 PTC Therapeutics
11.2.1 PTC Therapeutics Company Detail
11.2.2 PTC Therapeutics Business Overview
11.2.3 PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction
11.2.4 PTC Therapeutics Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2019-2024)
11.2.5 PTC Therapeutics Recent Development
11.3 Pfizer
11.3.1 Pfizer Company Detail
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction
11.3.4 Pfizer Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2019-2024)
11.3.5 Pfizer Recent Development
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Company Detail
11.4.2 Bristol-Myers Squibb Business Overview
11.4.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction
11.4.4 Bristol-Myers Squibb Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2019-2024)
11.4.5 Bristol-Myers Squibb Recent Development
11.5 Italfarmaco
11.5.1 Italfarmaco Company Detail
11.5.2 Italfarmaco Business Overview
11.5.3 Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction
11.5.4 Italfarmaco Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2019-2024)
11.5.5 Italfarmaco Recent Development
11.6 Santhera Pharmaceuticals
11.6.1 Santhera Pharmaceuticals Company Detail
11.6.2 Santhera Pharmaceuticals Business Overview
11.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction
11.6.4 Santhera Pharmaceuticals Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2019-2024)
11.6.5 Santhera Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Exondys
Table 3. Key Players of Emflaza
Table 4. Key Players of Translarna
Table 5. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (2019-2024) & (US$ Million)
Table 8. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Region (2019-2024)
Table 9. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 10. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Region (2025-2030)
Table 11. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Trends
Table 12. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Drivers
Table 13. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Challenges
Table 14. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Restraints
Table 15. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Players (2019-2024) & (US$ Million)
Table 16. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Players (2019-2024)
Table 17. Global Top Duchenne Muscular Dystrophy (DMD) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics as of 2023)
Table 18. Ranking of Global Top Duchenne Muscular Dystrophy (DMD) Therapeutics Companies by Revenue (US$ Million) in 2023
Table 19. Global 5 Largest Players Market Share by Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (CR5 and HHI) & (2019-2024)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Duchenne Muscular Dystrophy (DMD) Therapeutics Product Solution and Service
Table 22. Date of Enter into Duchenne Muscular Dystrophy (DMD) Therapeutics Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2019-2024) & (US$ Million)
Table 25. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Type (2019-2024)
Table 26. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 27. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Type (2025-2030)
Table 28. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2019-2024) & (US$ Million)
Table 29. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Application (2019-2024)
Table 30. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 31. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Application (2025-2030)
Table 32. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 33. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 34. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 35. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 37. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 38. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 39. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (2019-2024) & (US$ Million)
Table 40. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (2025-2030) & (US$ Million)
Table 41. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 42. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 43. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 44. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 46. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 47. Sarepta Therapeutics Company Detail
Table 48. Sarepta Therapeutics Business Overview
Table 49. Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product
Table 50. Sarepta Therapeutics Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2019-2024) & (US$ Million)
Table 51. Sarepta Therapeutics Recent Development
Table 52. PTC Therapeutics Company Detail
Table 53. PTC Therapeutics Business Overview
Table 54. PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product
Table 55. PTC Therapeutics Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2019-2024) & (US$ Million)
Table 56. PTC Therapeutics Recent Development
Table 57. Pfizer Company Detail
Table 58. Pfizer Business Overview
Table 59. Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Product
Table 60. Pfizer Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2019-2024) & (US$ Million)
Table 61. Pfizer Recent Development
Table 62. Bristol-Myers Squibb Company Detail
Table 63. Bristol-Myers Squibb Business Overview
Table 64. Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Product
Table 65. Bristol-Myers Squibb Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2019-2024) & (US$ Million)
Table 66. Bristol-Myers Squibb Recent Development
Table 67. Italfarmaco Company Detail
Table 68. Italfarmaco Business Overview
Table 69. Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Product
Table 70. Italfarmaco Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2019-2024) & (US$ Million)
Table 71. Italfarmaco Recent Development
Table 72. Santhera Pharmaceuticals Company Detail
Table 73. Santhera Pharmaceuticals Business Overview
Table 74. Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Product
Table 75. Santhera Pharmaceuticals Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2019-2024) & (US$ Million)
Table 76. Santhera Pharmaceuticals Recent Development
Table 77. Research Programs/Design for This Report
Table 78. Key Data Information from Secondary Sources
Table 79. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Type: 2023 VS 2030
Figure 3. Exondys Features
Figure 4. Emflaza Features
Figure 5. Translarna Features
Figure 6. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Application: 2023 VS 2030
Figure 8. Hospitals Case Studies
Figure 9. Clinics Case Studies
Figure 10. Home Care Case Studies
Figure 11. Duchenne Muscular Dystrophy (DMD) Therapeutics Report Years Considered
Figure 12. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 13. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 14. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Region: 2023 VS 2030
Figure 15. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Players in 2023
Figure 16. Global Top Duchenne Muscular Dystrophy (DMD) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics as of 2023)
Figure 17. The Top 10 and 5 Players Market Share by Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue in 2023
Figure 18. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 19. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Country (2019-2030)
Figure 20. United States Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Canada Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Country (2019-2030)
Figure 24. Germany Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. France Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. U.K. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Italy Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Russia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Nordic Countries Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Region (2019-2030)
Figure 32. China Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Southeast Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. India Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Australia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Country (2019-2030)
Figure 40. Mexico Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Brazil Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Country (2019-2030)
Figure 44. Turkey Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Saudi Arabia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Sarepta Therapeutics Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2019-2024)
Figure 47. PTC Therapeutics Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2019-2024)
Figure 48. Pfizer Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2019-2024)
Figure 49. Bristol-Myers Squibb Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2019-2024)
Figure 50. Italfarmaco Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2019-2024)
Figure 51. Santhera Pharmaceuticals Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2019-2024)
Figure 52. Bottom-up and Top-down Approaches for This Report
Figure 53. Data Triangulation
Figure 54. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
